n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
FORT MILL, SC / ACCESSWIRE / March 14, 2024 / Catheter Precision, Inc. (the “Company”) (NYSE American: VTAK), a U. S. -based medical device corporation, is a member of the U. S. The U. S. Department of Homeland Security, a U. S. department of medicine focused on cutting-edge electrophysiological products, announced that VIVO has been used in five procedures for the first time in Qatar at Hamad Medical Corporation Heart Hospital in Doha. Hamad Medical Corporation (HMC) is the leading provider of secondary and tertiary healthcare in Qatar and one of the leading hospital providers in the Middle East. HMC operates 12 hospitals: nine specialty hospitals and 3 network hospitals.
“VIVO was recently used for five patients at Doha Heart Hospital in Qatar,” said David Jenkins, CEO of Catheter Precision. He continued, “Clinicians have been inspired by VIVO’s precision and we look forward to expanding our presence in the Middle East and proceeding to showcase the benefits of VIVO in new territories. “
About VIVO
Catheter Precision’s VIVO™ (View Into Ventricular Onset) is a non-invasive, three-dimensional imaging formula that allows clinicians to identify the source of ventricular arrhythmias prior to surgery, streamlining workflow and reducing procedure time. VIVO has obtained marketing authorization from the U. S. FDA. It is located in the U. S. and has the CE mark.
About Catheter Accuracy
Catheter Precision is a cutting-edge medical device company based in the U. S. The U. S. Department of Health and Human Services (USA) is a company that brings to market new solutions to improve the treatment of cardiac arrhythmias. Their goal is to generate an innovative generation for electrophysiology procedures by collaborating with physicians and constantly advancing their products. Reincorporated as Ra Medical Systems, Inc. in Delaware in 2018, the company replaced its call to Catheter Precision, Inc. on August 17, 2023.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements. Forward-looking statements can be referred to by words such as “believe”, “anticipate”, “possibly”, “may also simply”, “possibly”, “may also simply”, “continue”, “expect”, “expect” , “extend”, “forecast”, “intend”, “predict”, “plan”, “trust”, “should”, “will”, “may”, “seek” or the negative form of these terms and other expressions similar, although not all forward-looking statements involve those words. Such forward-looking statements are subject to safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company’s expectations and ideals regarding such matters are likely not far-fetched. Actual results and effects could differ materially from those expressed in such forward-looking statements due to uncertainties, hazards and adjustments in circumstances, including, but not limited to, the hazards and uncertainties included under the heading “Risk Factors” in the company’s financial statements. the company. Form 10-. K filed with the SEC and available at www. sec. gov. These dangers and uncertainties include, but are not limited to, the fact that we will not be able to achieve profits unless we are able to achieve the expansion of our product and our expansion objectives. Our studies and advancement and commercialization efforts would likely involve entering into agreements with corporations. collaborators, we have entered into joint market placement agreements with respect to our products, and we would possibly enter into other joint market placement agreements, which will reduce our revenue from product sales, royalty agreements with respect to our LockeT device will decrease any long term benefits from that. productArray If we experience significant disruptions to our IT systems, our business may also be affected, litigation and other legal proceedings may also harm our business, if we make acquisitions or divestitures, we may also encounter difficulties that harm our business. our business, the lack of ability to attract and retain sufficient qualified personnel may also hinder our expansion, the lack of effective internal controls may also cause a loss of confidence to our investors and adversely affect the market value of our regular inventory. . If our internal controls are not effective, we may not be able to properly disclose our monetary effects or prevent fraud; our revenue would likely count on our consumers receiving a good enough reimbursement from insurers. personal and government-sponsored fitness programs, we could not possibly compete effectively with the corporations in our highly competitive industry, many of which have resources that we, our long-term operational effects depend on our ability to download parts in sufficient quantities on commercially reasonable terms or on schedules, values, quality and volumes acceptable to us, and suppliers may not deliver parts, or we may not be able to successfully service or discharge such parts on such terms, if hospitals, physicians and patients are not satisfied with our existing, long-term products or if the market for the indications for which a product candidate is approved is smaller than expected, we may not be able to generate significant revenue, if any, from our operations. medical devices are subject to the FDA’s widespread and ongoing regulatory requirements, our products would possibly be subject to additional recalls, revocations or suspensions after receiving approval. approval or clearance from the FDA or a foreign country, which can also divert the attention of managers and financiers. resources, harm our reputation and harm our business, adjustments in industrial policies between the United States and other countries, i. e. , the imposition of new or higher tariffs, may also put pressure on our average sales values as our consumers seek to compensate for having an The effect of an increase in customs duties on their own products, an increase in customs duties or the imposition of other barriers to foreign industry may also have an adverse effect on our income and the effects of our operations. In addition, the completion of the accounting for the merger by our auditor requires complex calculations and input from outside advisors and, therefore, the final effects of those calculations may also differ from our existing expectations. The dangers and uncertainties described above would likely be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or by other pandemics, disruptions in the chain of origin due to the war in Ukraine and other pandemics. other events, and through continued volatility in the stock markets and the U. S. economy generally.
Forward-looking statements included in this communication speak only as of the date hereof. The Company assumes no legal responsibility and does not intend to update those forward-looking statements, as required by law.
CONTACTS:
To the companyDavid Jenkins973-691-2000IR@catheterprecision. com
SOURCE: Catheter Precision, Inc.
Read the original press on accesswire. com